Result of AGM

9 June 2022

Instem plc
(“Instem” or the “Company”)

Result of AGM

Instem (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, announces that at its Annual General Meeting held today, all resolutions were duly passed. The results of the proxy voting position received in advance of the meeting are reported below:

No. Resolution For % For Against % Against Withheld
01 Accounts and Reports 13,886,707 89.98% 1,545,989 10.02% 2,094,614
02 Re-elect R A Bandali 17,527,120 100.00% 190 0.00% 0
03 Re-elect D M Sherwin 13,727,503 88.95% 1,705,343 11.05% 2,094,464
04 Re-elect M F McGoun 13,566,252 87.91% 1,866,594 12.09% 2,094,464
05 Re-appoint Auditors 17,527,120 100.00% 190 0.00% 0
06 Auditors Remuneration 17,527,310 100.00% 0 0.00% 0
07 Allot Shares 16,989,283 96.93% 538,027 3.07% 0
08 Allot Equity Securities 16,989,283 96.93% 538,027 3.07% 0
09 Make Market Purchases 17,527,310 100.00% 0 0.00% 0

 

For further information, please contact:

Instem plc Via Walbrook
Phil Reason, CEO  
Nigel Goldsmith, CFO  
Singer Capital Markets (Nominated Adviser & Joint Broker) +44 (0) 20 7496 3000
Peter Steel  
Alex Bond  
Rachel Hayes  
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Ben Maddison  
Alex Price  
Wallbrook Financial PR Tel: +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome  

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit instem.com.